X0206 3/A 2018-10-18 2018-10-19 0 0001664106 LogicBio Therapeutics, Inc. LOGC 0001700449 Arix Bioscience plc 20 BERKELEY SQUARE MAYFAIR, LONDON X0 W1J 6EQ UNITED KINGDOM 0 0 1 0 0001756884 Arix Bioscience Holdings Ltd 20 BERKLEY SQUARE MAYFAIR, LONDON X0 W1J6EQ UNITED KINGDOM 0 0 1 0 Series B Convertible Preferred Stock Common stock 2279023 I See footnote The Series B Convertible Preferred Stock is convertible into shares of common stock of LogicBio Therapeutics, Inc. (the "Issuer") at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series B Convertible Preferred Stock. These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This filing amends the Form 3 filed on October 19, 2018 to reflect the addition of Arix Bioscience Holdings Limited as a Reporting Owner and signatory hereto. Arix Bioscience Holdings Limited had not yet obtained EDGAR access codes at the time of the prior Form 3 filing and has since obtained such codes. Arix Bioscience Plc, by: /s/ James Rawlingson, Chief Financial Officer 2018-10-25 Arix Bioscience Holdings Limited, by: /s/ James Rawlingson, Authorized Officer 2018-10-25